Clinical Trial

Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure

Study acronym: HEAL-AHF
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.
Protocol Amendment History 1 change
notable Sponsor changed: Help Therapeutics -> HELP Therapeutics Co., Ltd. 2026-04-05
Trial Details
NCT Number NCT06340048
Lead Sponsor Help Therapeutics
Collaborators: TEDA International Cardiovascular Hospital
Conditions Heart Failure
Enrollment 36 participants
Start Date 2023-09-05
Primary Completion 2026-11-10 (estimated)
Study Completion 2027-05-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-10